^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD79b-targeted antibody-drug conjugate

    Related drugs:
    4d
    Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR-T Therapy. (PubMed, EJHaem)
    In our study, we included 51 adult patients with LBCL treated with axicabtagene ciloleucel. Consistently negative patients may be suboptimal candidates for anti-CD19 CAR-T therapy. Alternative therapeutic options, such as bispecific antibodies or polatuzumab-based regimens, could be considered for this subset of patients.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    Yescarta (axicabtagene ciloleucel) • Polivy (polatuzumab vedotin-piiq)
    1m
    Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma. (PubMed, Ann Hematol)
    No abstract available
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    bendamustine • Polivy (polatuzumab vedotin-piiq)
    1m
    Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Jul 2025
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq)
    1m
    Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P3, N=306, Active, not recruiting, GWT-TUD GmbH | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Oct 2024 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)
    1m
    Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Medical College of Wisconsin | Initiation date: Dec 2024 --> Jun 2025
    Trial initiation date
    |
    clonoSEQ
    |
    doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    1m
    SUNMO: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P3, N=242, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Feb 2025 --> May 2025
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    1m
    A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Dec 2026 --> May 2027
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    Polivy (polatuzumab vedotin-piiq)
    2ms
    Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL (clinicaltrials.gov)
    P2, N=30, Recruiting, Affiliated Hospital of Nantong University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • Polivy (polatuzumab vedotin-piiq)
    2ms
    Efficacy and Safety of Pola-RCHP-X Vs Pola-RCHP in Untreated DLBCL (clinicaltrials.gov)
    P2, N=152, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • decitabine • prednisone • Polivy (polatuzumab vedotin-piiq)
    2ms
    POSS: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • bendamustine • Polivy (polatuzumab vedotin-piiq)
    2ms
    POLARGO: A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=270, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Nov 2024
    Trial completion • Trial completion date
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Polivy (polatuzumab vedotin-piiq)
    2ms
    Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model. (PubMed, BMJ Open)
    Pola-R-CHP is not cost-effective in the first-line treatment for previously untreated CD20-positive DLBCL in China. A value-based price for the cost of pola is less than US$33.19/mg.
    Journal • HEOR • Cost-effectiveness
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq)
    2ms
    An exploratory clinical study of polatuzumab vedotin plus obinutuzumab and dose-adjusted GDP regimen in patients with transplantation-eligible relapsed or refractory diffuse large B-cell lymphoma (ChiCTR2400092813)
    P4, N=55, Beijing Hospital; Beijing Hospital
    New P4 trial
    |
    cisplatin • gemcitabine • Gazyva (obinutuzumab) • dexamethasone • Polivy (polatuzumab vedotin-piiq)
    2ms
    A Prospective, Single-Arm, Single-Center Study of Pola-ZR2 (Polatuzumab vedotin, Zanubrutinib, Lenalidomide and Rituximab) in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma (ChiCTR2400092588)
    P2, N=33, Recruiting, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of
    New P2 trial
    |
    Rituxan (rituximab) • lenalidomide • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq)
    2ms
    Efficacy and Safety of Polatuzumab Vedotin combined with rituximab and dexamethasone in the treatment of elderly fragile patients with newly diagnosed diffuse large B-cell lymphoma (ChiCTR2400092977)
    P2, N=32, Beijing hospital; Beijing Hospital
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Polivy (polatuzumab vedotin-piiq) • dexamethasone injection
    3ms
    POLA-R-CHP in the First-line Treatment of Transformed DLBCL (clinicaltrials.gov)
    P2, N=20, Recruiting, Fudan University
    New P2 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq)
    3ms
    CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). (clinicaltrials.gov)
    P2, N=22, Recruiting, Lazaros Lekakis | N=40 --> 22
    Enrollment change • CAR T-Cell Therapy
    |
    CD19 positive
    |
    Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    3ms
    A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with High-risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Jennifer Crombie, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive • MYC translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    3ms
    POSS: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna
    New trial
    |
    Rituxan (rituximab) • bendamustine • Polivy (polatuzumab vedotin-piiq)
    4ms
    Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study. (PubMed, Hematol Oncol)
    While 12-month PFS failed to reach statistical significance, subgroup analyses favor Pola-R-CHP. Further research with a wider population, longer follow-up, and screening of advantageous groups are warranted.
    Retrospective data • Journal • Real-world evidence • IO biomarker • Real-world
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • KMT2D (Lysine Methyltransferase 2D) • PIM1 (Pim-1 Proto-Oncogene) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    TP53 mutation • PIM1 mutation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq)
    5ms
    R-Pola-Glo: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP (clinicaltrials.gov)
    P2, N=125, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Active, not recruiting --> Recruiting | N=80 --> 125 | Trial primary completion date: Sep 2027 --> Apr 2025
    Enrollment open • Enrollment change • Trial primary completion date • Combination therapy
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    5ms
    A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL (clinicaltrials.gov)
    P2, N=39, Recruiting, University of Rochester | Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq)
    5ms
    NCI-2021-12489: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Mar 2025 | Trial primary completion date: Dec 2025 --> Mar 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    5ms
    G-Pola-ZLP in Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Navy General Hospital, Beijing
    New P2 trial
    |
    lenalidomide • Brukinsa (zanubrutinib) • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    5ms
    Pola-ZR2P in Previously Untreated DLBCL (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Navy General Hospital, Beijing
    New P2 trial
    |
    Rituxan (rituximab) • lenalidomide • Brukinsa (zanubrutinib) • prednisone • Polivy (polatuzumab vedotin-piiq)
    5ms
    Treatment of refractory diffuse large B-cell lymphoma involving the central nervous system with polatuzumab vedotin-based regimen: a case report and literature review (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    Her initial treatment comprised chemo-free therapy and radiotherapy, followed by progression. In the second-line treatment, a Pola-based regimen was applied, and the patient achieved a complete response, suggesting that this regimen may be a therapeutic option for patients with DLBCL involving the central nervous system.
    Retrospective data • Review • Journal
    |
    CD79B (CD79b Molecule)
    |
    Polivy (polatuzumab vedotin-piiq)
    6ms
    A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Hoffmann-La Roche | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • Real-world evidence • Real-world
    |
    Polivy (polatuzumab vedotin-piiq)
    6ms
    POLARIX: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=1000, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive • BCL6 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq)
    6ms
    Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease. (PubMed, Clin Lymphoma Myeloma Leuk)
    In a single center real world retrospective analysis of R/R LBCL patients with available genomic data, polatuzumab based therapy may be less effective in patients with HGBL-NOS or MYC/BCL2 histology and MYC rearrangements, but not in patients with GCB COO LBCL without these features. Routine performance of more comprehensive pathologic analysis of tumors may inform the use of polatuzumab based therapy in patients with LBCL.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC rearrangement
    |
    Polivy (polatuzumab vedotin-piiq)
    6ms
    SUNMO: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P3, N=222, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> Feb 2027 | Trial primary completion date: May 2025 --> Feb 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    6ms
    Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2; N=31; Not yet recruiting; Sponsor:Medical College of Wisconsin
    New P2 trial
    |
    clonoSEQ
    |
    doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    6ms
    Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=3, Terminated, Academic and Community Cancer Research United | N=63 --> 3 | Trial completion date: Apr 2029 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2027 --> Mar 2024; Trial closed due to low accrual rate
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq)
    7ms
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=68, Recruiting, University of Washington | Suspended --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Neupogen (filgrastim)
    7ms
    Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma. (PubMed, Cancer Discov)
    See related article by Corcoran et al., p. 1653 (6) See related article by Meriranta et al. (7).
    Journal
    |
    CD79B (CD79b Molecule) • KLHL6 (Kelch Like Family Member 6)
    |
    Polivy (polatuzumab vedotin-piiq)
    7ms
    Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2024 --> Dec 2024
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq)
    7ms
    A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial • Combination therapy
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • bendamustine • Polivy (polatuzumab vedotin-piiq)
    7ms
    Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma (clinicaltrials.gov)
    P2, N=41, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2027 --> Mar 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    8ms
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=68, Suspended, University of Washington | N=50 --> 68
    Enrollment change
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Neupogen (filgrastim)
    8ms
    POTENT: The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=100, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • lenalidomide • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq)
    8ms
    The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=100, Not yet recruiting, Ruijin Hospital
    New P3 trial
    |
    Rituxan (rituximab) • lenalidomide • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq)
    8ms
    R-Pola-Glo: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    8ms
    A single-center, observational study of polatuzumab vedotin-based regimen for older patients with relapsed/refractory diffuse large B-cell lymphoma (ChiCTR2400082122)
    P=N/A, N=47, Not yet recruiting, Beijing Hospital; Beijing Hospital
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Polivy (polatuzumab vedotin-piiq)